Drug intelligence / Profile preview

ALG-006780

Development stage: Preclinical
Lead developer: Aligos Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ALG-006780 is a novel, non-HAP class A capsid assembly modulator (CAM-A) developed by Aligos Therapeutics for the treatment of chronic hepatitis B virus (HBV) infection. It acts as a potent inhibitor of HBV RNA encapsidation and covalently closed circular DNA (cccDNA) establishment in infected hepatocytes. Preclinical studies demonstrate that ALG-006780 induces rapid and significant reductions in serum HBV DNA, HBsAg, and HBeAg levels in animal models, with favorable pharmacokinetic properties. The compound also induces HBc-dependent cell death selectively in cells overexpressing hepatitis B core antigen (HBc), confirming its mechanism of action as a CAM-A targeting the viral capsid assembly process[1][2][3].

Targets

HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on ALG-006780.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALG-006780.

Explore the full profile